Skip to main content Accessibility help
  • Print publication year: 2013
  • Online publication date: June 2014


Suggested reading

Boneva N, Brenner T, Argov Z. Gabapentin may be hazardous in myasthenia gravis. Muscle and Nerve 2000; 23: 1204–1208.
Chadwick D, Leiderman DB, Sauermann W, Alexander J, Garofalo E. Gabapentin in generalized seizures. Epilepsy Research 1996; 25: 191–197.
Fink K, Dooley DJ, Meder WP, Suman-Chauhan N, Duffy S, Clusmann H, Gothert M. Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 2002; 42: 229–236.
Fujii H, Goel A, Bernard N, Pistelli A, Yates LM, Stephens S, Han JY, Matsui D, Etwell F, Einarson TR, Koren G, Einarson A. Pregnancy outcomes following gabapentin use: Results of a prospective comparative cohort study. Neurology 2013; 80: 1565–1570.
Gidal BE, Radulovic LL, Kruger S, Rutecki P, Pitterle M, Bockbrader HN. Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Research 2000; 40: 123–127.
Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Reviews in Neurotherapeutics 2010; 10: 119–140.
McLean MJ, Gidal BE. Gabapentin dosing in the treatment of epilepsy. Clinical Therapeutics 2003; 25: 1382–1406.
Ohman I, Vitolis S, Tomson T. Pharmacokinetics of gabapentin during delivery, in the neonatal period and lactation. Epilepsia 2005; 46: 1621–1624.
Patsalos PN. Antiepileptic drug interactions: a clinical guide, 2nd edition. 2013, Springer, London, UK; 2013.
Vollmer KO, von Hodenberg A, Kolle EU. Pharmacokinetics and metabolism of gabapentin in rat, dog and man. Arzneim Forsch Drug Research 1988; 36: 830–839.
Wolf SM, Shinner S, Kang H, Gil KB, Moshe SL. Gabapentin toxicity in children manifesting as behavioural changes. Epilepsia 1995; 36: 1203–1205.